



# Resource impact template

Resource impact

Published: 31 January 2024

Last updated: 11 March 2024

[www.nice.org.uk](http://www.nice.org.uk)

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for diffuse large B-cell lymphoma after 2 or more systemic treatments:

- [Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments](#) (2024) NICE technology appraisal guidance 954
- [Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments](#) (2024) NICE technology appraisal guidance 947
- [Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments](#) (2023) NICE technology appraisal guidance 927
- [Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies](#) (2023) NICE technology appraisal guidance 872